Back

AbbVie Inc

Ticker: ABBV ISIN: US00287Y1091
Add to portfolio Portfolio analysis in 2min
Stock Large-cap Dividend payer Trading above 200-day average Near 52-week high
Market cap
$462.68B
P/E
75.24
Forward P/E
18.94
Profit margin
9.80%
Revenue growth QoQ
10.20%
Div. yield
2.57%
Beta
0.28
$255.00 1.63%
Price as of 2026-09-10 · NYSE

Performance by timeframe

Rolling returns
1 Month +2.51%
6 Months +17.87%
1 Year +19.39%
5 Years +23.32% p.a.+185.06%
10 Years +19.78% p.a.+506.93%
Since inception +20.19% p.a.+1,153.42%
Calendar year returns
YTD +14.24%
2025 +33.08%
2024 +18.87%
2023 -0.23%
2022 +24.01%
2021 +32.43%

Key stats

Market cap
462.68B
P/E
75.24
Dividend yield
2.57%
Beta
0.28
52-week range
189.40 - 267.47
50-day MA
247.19
200-day MA
226.30
Section 1

Business overview

Company profile data from fundamentals.

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Sector Healthcare
Industry Drug Manufacturers - General
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 62.25%
ROA 10.51%
Profit margin 9.80%
Operating margin 40.04%
PEG ratio 0.43
Revenue/share TTM 36.39
Revenue TTM 64.39B
EBITDA 30.76B
Gross profit TTM 46.87B
Beta 0.28

Valuation

Trailing P/E 75.24
Forward P/E 18.94
P/B 50.46
P/S 7.19
EV/EBITDA 27.42
EV/Revenue 8.30
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 14.01
Quarterly earnings growth 2.90%
Revenue TTM 64.39B
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 2.57%
Dividend per share 6.8300
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Ownership & short interest

Short ratio 3.69
Short % of float 1.42%

Details

Instrument metadata and source update timestamps.

Symbol ABBV
Name AbbVie Inc
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US00287Y1091
Country USA
Code + exchange ABBV.NYSE
Last price date 2026-08-20
Fundamentals updated 2026-08-21

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.